Glaxo Executives Cited in Case Now Lead Sanofi, Actelion – Businessweek


GPB

Glaxo Executives Cited in Case Now Lead Sanofi, Actelion
Businessweek
Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies.
Glaxo Settlement Pulls Back Curtain On Drug MarketingNPR (blog)

all 36 news articles »

View full post on asthma – Google News

Targacept CEO steps down, leaves board – BusinessWeek


Citybizlist

Targacept CEO steps down, leaves board
BusinessWeek
The departure comes as the company has slashed its work force to cut costs after ending development of an experimental depression drug and setbacks in tests of another drug to treat asthma and diabetes. Its shares are down more than 80 percent in the
Biopharma company Targacept says CEO resignsReuters
Targacept's CEO stepping down in reshuffleMarketWatch

all 35 news articles »

View full post on asthma – Google News

AEP disputes study linking plants to 3200 deaths – BusinessWeek


kjrh.com

AEP disputes study linking plants to 3200 deaths
BusinessWeek
By JUSTIN JUOZAPAVICIUS Energy giant American Electric Power is disputing an environmental group's study that finds air pollution from the company's 26 coal-fired plants caused as many as 3200 deaths and more than 20000 asthma attacks last year.
Americans File More than 735000 Comments in Support of Limits on Carbon PollutionNatural Resources Defense Council (blog)

all 55 news articles »

View full post on asthma – Google News

Targacept: Drug missed goal due to analysis error – BusinessWeek


Citybizlist

Targacept: Drug missed goal due to analysis error
BusinessWeek
Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent,
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of MarketWatch (press release)
Targacept reports error in asthma studyTriad Business Journal
Targacept loses big shareholder, finds error in previous studyWinston-Salem Journal
Wall Street Journal
all 22 news articles »

View full post on asthma – Google News

Targacept slips on mixed results from drug studies – BusinessWeek

Targacept slips on mixed results from drug studies
BusinessWeek
Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of MarketWatch (press release)
Targacept discontinues two clinical trials, reports success with a thirdWinston-Salem Journal (blog)
Asthma drug shows promise, diabetes study fails in Targacept phase 2 trialsMedCity News

all 41 news articles »

View full post on asthma – Google News

Theravance Falls Most in 3 Years After Glaxo Drug Fails – BusinessWeek


Visit Bulgaria

Theravance Falls Most in 3 Years After Glaxo Drug Fails
BusinessWeek
The company, based in South San Francisco, California, said in a statement today that Relovair, its drug for asthma and chronic obstructive pulmonary disease, proved no better than Glaxo's Seretide in a clinical trial. Relovair is “the most important
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)
Glaxo on the slide after trials setback for asthma drugEvening Standard
Theravance Shares Slide on Lung Drug DeathsTheStreet.com
Visit Bulgaria –Wall Street Journal (India) –FierceBiotech
all 73 news articles »

View full post on asthma – Google News

Asthma Plans Shouldn’t Affect Payments, Study Finds – BusinessWeek


HealthNewsDigest.com

Asthma Plans Shouldn't Affect Payments, Study Finds
BusinessWeek
Oct. 4 (Bloomberg) — A common measure of how well hospitals treat children and teens with asthma is statistically meaningless and shouldn't be used to determine federal quality payments under the health-care law, a study found.
Hospital asthma grades not linked to healthier kidsReuters
Relevance of Kids' Asthma Care Measure QuestionedMedPage Today
Asthma Care Measures Don't Reflect Outcomes in ChildrenFamily Practice News Digital Network
Doctors Lounge –HealthNewsDigest.com
all 20 news articles »

View full post on asthma – Google News

Asthma Home-Care Plans Shouldn’t Affect Payments, Study Finds – BusinessWeek


HealthNewsDigest.com

Asthma Home-Care Plans Shouldn't Affect Payments, Study Finds
BusinessWeek
Oct. 4 (Bloomberg) — A common measure of how well hospitals treat children and teens with asthma is statistically meaningless and shouldn't be used to determine federal quality payments under the health-care law, a study found.
Relevance of Kids' Asthma Care Measure QuestionedMedPage Today
Asthma Care Measures Don't Reflect Outcomes in ChildrenFamily Practice News Digital Network
For Kids With Asthma Flu Season Is More DangerousHealthNewsDigest.com
EurekAlert (press release) –Journal of American Medical Association (subscription)
all 10 news articles »

View full post on asthma – Google News